Eternygen is focused on the discovery of inhibitors of NaCT, a novel target which, “as the longevity gene”, is also known as INDY (“I am Not Dead Yet”), for the treatment of dietary-related metabolic diseases.
VIEW WEBSITE >>
Location: Germany, Berlin
Employees: 51-200
Founded date: 2012